Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacodynamic and pharmacokinetic properties of insulin glulisine (Apidra) in comparison to insulin lispro (Humalog) in healthy lean and obese subjects

Next Previous
Trial Profile

Pharmacodynamic and pharmacokinetic properties of insulin glulisine (Apidra) in comparison to insulin lispro (Humalog) in healthy lean and obese subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glulisine (Primary) ; Insulin lispro
  • Indications Diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Sanofi

Most Recent Events

  • 15 Dec 2009 Actual initiation date (Apr 2004) and actual end date (Oct 2004) added as reported by ClinicalTrials.gov.
  • 12 Sep 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top